SPINEART ACADEMY IN SAN DIEGO, USA
Spineart Academy in San Diego, USA
Last week Spineart hosted a lab in San Diego where 40 participants from the USA, Brazil, Mexico, Colombia and Taiwan had the opportunity to learn more about the latest innovations in total cervical disc replacement, management of adult scoliosis and minimally invasive treatment methods for degenerative conditions.
All participants had the opportunity to train on M.I.S. surgical techniques through interactive presentations and hands-on anatomical workshops. Thanks to prominent surgeon faculty from the USA, Mexico and Spain, it was a successful and informative course!
10’000 BAGUERA® C IMPLANTED WORLDWIDE
Spineart is pleased to announce that, as of the 1st of November 2013, more than 10’000 BAGUERA® C have been implanted successfully worldwide. The first surgery was held in France in January 2007.
The success of the BAGUERA® C can be attributed to its main key features such as its anatomical shape, easy insertion, shock-absorption, guided mobile PE nucleus and MRI compatibility. All Spineart implants are sterile packed and bar-coded for increased safety, procedure compliance and cost-efficiency.
This implant is not available in the US. For more information, please contact us at contact@spineart.com
1’000 ROMEO®2 PAD MIS POSTERIOR AXIAL FUSION DEVICES IMPLANTED WORLDWIDE
Geneva, September 6, 2013. Spineart is pleased to announce that, as of the 31st of July 2013, more than 1’000 ROMEO®2 PAD have been implanted successfully worldwide. The first surgery was held in Fribourg, Switzerland, in November 2011 and the device was commercially launched in June 2012. Since then, this device has been implanted in 14 countries.
ROMEO®2 PAD, is a minimally invasive posterior axial fusion device used to provide spinal fixation in lumbar fusion procedures. The ROMEO®2 PAD is a safe and simple to use one step alternative to pedicle screw fixation and can be used to treat a number of spinal conditions with much less tissue trauma than traditional spinal fixation systems.
All Spineart implants are sterile packed and bar-coded for increased safety, procedure compliance and cost-efficiency.
For more information, please contact us at contact@spineart.com
SPINEART ACQUIRES WORLDWIDE RIGHTS TO ΒGEL® BONE SUBSTITUTE GEL
Spineart announced today that it acquired a portfolio of proprietary synthetic orthobiologic solutions from Orthos Ltd including the worldwide rights to βGel® and βGran®.
βGel® is an innovative osteoconductive scaffold in the form of a versatile, pre-mixed, malleable gel with unique handling characteristics even when compared to allografts. βGel® stiffens and becomes resistant to displacement by body fluids as it reaches body temperature. Its interconnected porosity is controlled to provide a three-dimensional scaffold that supports vascularisation and early cell attachment in order to function as an osteoconductive template.
βGran® is a range of high purity synthetic osteoconductive scaffolds intended to be used as bone void fillers in the treatment of osseous defects which occur as a result of trauma or in surgically created defects. βGran® has been successfully used to treat bone loss resulting from trauma to resolve conduction defects in non-unions and to restore conduction across osteotomy sites. In spinal fusion βGran® has proved extremely effective at expanding the volume of available fusion material as it can be combined with any autograft harvested during the surgical procedure.
About Spineart :
Spineart delivers pioneering, safe and efficient solutions to spine surgeons, operating room teams and patients.
Spineart, present in 47 countries, offers a full range of high quality Swiss Made Fusion, Motion, and MIS devices worldwide, focusing on simplicity and safety of use.
Spineart markets a complete portfolio of traceable barcoded sterile packed implants and is thereby proudly promoting higher safety, cost-efficiency, and compliance at the hospital.
For more information please contact us at contact@spineart.com or visit spineart.com.
LAUNCH OF ROMEO®2 25D DEFORMITY SCREW
Spineart today announced that its ROMEO®2 25D deformity screw was used for the first time in a spinal deformity surgery. The surgery was performed successfully at the University of California, Irvine Medical Center by Dr. Nitin Bhatia, Chief of Spinal Surgery, and Dr. S. Samuel Bederman, Fellowship-trained orthopaedic spine surgeon specializing in complex deformity reconstruction and degenerative disorders. “The use of the ROMEO®2 25D deformity screw allowed us to correct the patients scoliosis more safely and effectively than may have otherwise been possible,” said Dr. Bhatia.
The development of the ROMEO®2 25D deformity pedicle screw marks a technological leap forward in treating complex spinal deformities. The new innovative screw conveniently combines the advantages of a monaxial and polyaxial screw and assists in coronal corrections by segmentally pulling the spine to match a contoured rod and in axial correction by de-rotating the vertebral body during rod reduction. When using the ROMEO®2 25D deformity screw, forces are spread over multiple levels which help reduce the risk of screw pullout during reduction maneuvers.
For more information please contact us at contact@spineart.com
About Spineart:
Spineart delivers pioneering, safe and efficient solutions to spine surgeons, operating room teams and patients.
Spineart, present in 47 countries, offers a full range of high quality Swiss Made Fusion, Motion, and MIS devices worldwide, focusing on simplicity and safety of use.
Spineart markets a complete portfolio of traceable barcoded sterile packed implants and is thereby proudly promoting higher safety, cost-efficiency, and compliance at the hospital.
SPINEART ACCELERATES ITS INTERNATIONAL DEVELOPMENT THROUGH ITS NEWLY ESTABLISHED GERMAN SUBSIDIARY
Geneva, July 1st, 2013.
Spineart accelerates its international development through its newly established German subsidiary.
Spineart announced today the opening of its German subsidiary, Spineart GmbH, effective July 1st 2013.
After 3 years of a successful and fruitful collaboration, Spineart and Sanofi-Aventis mutually agreed to terminate their exclusive distribution agreement in Germany. As part of the agreement Spineart Deutschland GmbH will progressively take over Sanofi Spine German distribution activities and sell directly in Germany, the largest European spine market. A transition period until the end of the year will allow a smooth and professional business transition.
In line with its strategy to address major markets, Spineart is now selling directly in the US, France, Switzerland, Italy, Austria and Germany with more announcements to be made before the end of the year.
About Spineart:
Spineart delivers pioneering, safe and efficient solutions to spine surgeons, operating room teams and patients.
Spineart, present in 47 countries, offers a full range of high quality Swiss Made Fusion, Motion, and MIS devices worldwide, focusing on simplicity and safety of use.
Spineart markets a complete portfolio of traceable barcoded sterile packed implants and is thereby proudly promoting higher safety, cost-efficiency, and compliance at the hospital.1